Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Antismoking drug still recommended to Canadians despite side effects and US advisory

Roger Collier
CMAJ February 17, 2009 180 (4) 381; DOI: https://doi.org/10.1503/cmaj.090114
Roger Collier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

A spate of complaints about the smoking-cessation drug varenicline (Champix) prompted bans on its use by pilots and commercial drivers in the United States last year, but reports of adverse reactions have not resulted in such dramatic consequences for Canadian users.

“At this time, Health Canada considers that, when used as directed, the benefits associated with Champix as a smoking cessation therapy continue to outweigh the overall risks,” stated Health Canada spokesperson Paul Duchesne via email.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

The benefits of the smoking-cessation drug varenicline outweigh the risks, according to Health Canada. Image by: Photos.com

Pfizer introduced the drug in the United States, where it's marketed under the brand name Chantix, in September 2006. It is now marketed in 73 countries and, according to Pfizer, has been taken by some 10 million people worldwide.

Side effects of the drug include nausea and abnormal dreams. Because of growing evidence of a link to aggression, depression and suicidal tendencies, on Feb. 1, 2008, the US Food and Drug Administration issued a public health advisory that warned users and doctors about the neuropsychiatric symptoms. When the drug went on sale in Australia, in January 2008, the Therapeutic Goods Administration ordered Pfizer to issue “Dear Doctor” letters. The United Kingdom's Medicines and Healthcare Products Regulatory Agency received 3541 adverse effects reports, including 10 suicides, within a year of varenicline hitting the market in September 2006.

“It is not known whether these events are occurring at a rate and severity which is different from the background rate for smoking cessation in the general population, or in the psychiatric population (treated or untreated), or different from the rates for other drugs in the class of smoking cessation,” stated Pfizer Canada Inc. spokesperson Christian Marcoux via email.

Last October, the US Institute for Safe Medication Practices linked varenicline to cardiac rhythm disturbances and cases of acute myocardial infarction. It reported that US users were involved in 1001 serious incidents in the first quarter of 2008, including many traffic accidents.

The US Federal Aviation Administration promptly banned pilots and air traffic controllers from using varenicline. Transport Canada, which has doctors who assess aviation professionals individually, has not followed suit. “We will not intervene if the pilot is deemed fit to fly,” says spokesperson Maryse Durette.

The US Federal Motor Carrier Safety Administration banned varenicline for all drivers of commercial motor vehicles. But the Canadian Council of Motor Transport Administrators has not banned the drug, choosing instead to evaluate drivers on a case-by-case basis. “It's not the medication. It's the medical condition you have that doesn't make you fit,” says Ian Tomlinson, the council's program manager.

Health Canada approved varenicline for sale in Canada on Jan. 24, 2007. According to Pfizer, Canadian doctors have to date issued more than 1.1 million prescriptions for the drug. Health Canada received 818 reports of adverse effects from varenicline users as of Oct. 31, 2008, and has issued 2 warnings about the drug, the most recent (Jan. 6) stating that it was “in the process of further strengthening the labelling for the drug with respect to the risk of serious psychiatric adverse effects.”

The effect of adverse event reports on sales has yet to be felt in Canada, but sales of varenicline are down sharply in the US. In the third-quarter of 2008, sales totalled US$96 million, a drop of nearly half from the same quarter in 2007.

In spite of the warnings, some Canadian health organizations still recommend varenicline to people attempting to quit smoking. The Canadian Lung Association endorses the drug under its generic name on its website. The Canadian Cancer Society recommends smoking-cessation products in general but does not endorse specific products, according to spokesperson Alexa Giorgi. Dr. Peter Selby, who heads the Nicotine Dependence Clinic at the Centre for Addiction and Mental Health, says varenicline is appropriate for some people. “We are not comparing the risks to a placebo,” he says. “We are comparing it to not quitting smoking. We have to intervene appropriately.”

Selby, who has received fees for research, consultation and training from Pfizer, says that people who opt for pharmaceutical help to quit smoking must be vigilant in monitoring side effects and reporting them to their doctors. “The take-home message is that you have to weigh the risks and benefits with the patient.”

Health Canada continues to monitor the safety of varenicline and is updating prescribing information. When this is completed, new advice will be sent to health professionals and released to the public. Duschesne says Health Canada does not automatically compile information comparing the number of adverse effects reported for different drugs, but writes: “It is however fair to say that adverse events reported by Champix users have been increasing significantly in the last few months.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 180 (4)
CMAJ
Vol. 180, Issue 4
17 Feb 2009
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antismoking drug still recommended to Canadians despite side effects and US advisory
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antismoking drug still recommended to Canadians despite side effects and US advisory
Roger Collier
CMAJ Feb 2009, 180 (4) 381; DOI: 10.1503/cmaj.090114

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Antismoking drug still recommended to Canadians despite side effects and US advisory
Roger Collier
CMAJ Feb 2009, 180 (4) 381; DOI: 10.1503/cmaj.090114
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Drug regulation
    • Drugs: adverse reactions

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire